# LEGEND-T2DM Evidence Dissemination Summary

- Target (class): **Linagliptin** (DPP-4 inhibitors)
- Comparator (class): **Glyburide** (Sulfonylureas)
- Outcome: **Renal cancer**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	-	-	-	-
Merative CCAE	5,630	3,838	9	2.35
Merative MDCD	2,750	1,873	<5	<2.67
Merative MDCR	1,020	932	<5	<5.36
Optum Clinformatics	12,298	9,870	19	1.93
Optum EHR	6,425	1,263	<5	<3.96
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)

What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)